Vimarsana
Biggest News Aggregation in the World

David Bharucha News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from David Bharucha. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In David Bharucha Today - Breaking & Trending Today

Positive Results from ReVeRA Phase 2 Study of Etripamil Nasal Spray in AFib-RVR Presented by Milestone Pharmaceuticals during AHA 2023 - Vimarsana News

Positive Results from ReVeRA Phase 2 Study of Etripamil Nasal Spray in AFib-RVR Presented by Milestone Pharmaceuticals during AHA 2023

Published: November 25, 2023

Milestone Pharmaceuticals Inc. recently announced positive Phase 2 data that show etripamil nasal spray resulted in rapid and statistically superior ventricular rate reduction and improved symptom-relief in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) compared to placebo. The findings were presented during the American Heart Association Scientific Sessions 2023, held recently in Philadephia, PA.

Source: dicardiology.com
Related Topics:
City OfUnited KingdomUnited StatesOlmsted CountyA John CammDavid BharuchaCardiology Clinical Academic GroupMilestone Pharmaceuticals IncClinical Sciences Research InstituteDuring The American Heart Association Scientific SessionsMilestone PharmaceuticalsAmerican Heart Association Council On EpidemiologyGeorge University Of LondonPrevention Statistics CommitteeA Report From The American Heart AssociationDrug AdministrationAmerican Heart Association Scientific SessionsBritish Heart Foundation Emeritus ProfessorClinical CardiologyChief Medical OfficerControlled StudyEtripamil Nasal SprayScience SessionTreatment Satisfaction QuestionnaireHeart Association Council
Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023 - Vimarsana News

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Published: November 11, 2023

Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate  compared to...

Source: marketscreener.com
Related Topics:
United KingdomCity OfUnited StatesOlmsted CountyIsrael GeneralDavid BharuchaA John CammKim FoxPrevention Statistics CommitteeClinical Sciences Research InstituteCardiology Clinical Academic GroupMilestone PharmaceuticalsGeorge UniversityAmerican Heart Association Council On EpidemiologyDrug AdministrationExchange CommissionAmerican Heart AssociationMilestone Pharmaceuticals IncFeatured ScienceHeart AssociationScientific SessionsJohn CammBritish Heart Foundation Emeritus ProfessorClinical CardiologyChief Medical Officer
Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023 - Vimarsana News

Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

Published: September 27, 2023

/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2...

Source: prnewswire.com
Related Topics:
United KingdomUnited StatesCity OfDavid BharuchaKim FoxMilestone Pharmaceuticals IncGeorge University Of LondonClinical Sciences Research InstituteAmerican Heart AssociationExchange CommissionMilestone PharmaceuticalsCardiology Clinical Academic GroupPrnewswire Milestone Pharmaceuticals IncCenters For DiseaseUs Securities Exchange CommissionScientific SessionsFeatured Science PresentationChief Medical OfficerFeature ScienceFeatured ScienceBritish Heart Foundation Emeritus ProfessorClinical CardiologyControlled StudyEtripamil Nasal SprayAcute Reduction
Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet - Vimarsana News

Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet

Published: June 20, 2023

- Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventricular tachycardia to sinus rhythm within 30 minutes...

Source: prnewswire.com
Related Topics:
United StatesDavid PittsBruce StamblerDavid BharuchaKaplan MeierUs Securities Exchange CommissionPiedmont Heart InstituteMilestone Pharmaceuticals IncExchange CommissionMilestone PharmaceuticalsLead AuthorChief Medical OfficerIntranasal Etripamil UsingRepeat Dose RegimenNorth AmericaAbout Paroxysmal SupraventricularSupraventricular TachycardiaPrivate Securities Litigation Reform Act
Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update - Vimarsana News

Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update

Published: May 12, 2022

/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

Source: prnewswire.com
Related Topics:
United StatesDavid BharuchaDavid PittsJoseph OlivetoBruce StamblerSean PokorneyDuke University School Of MedicineMontreal Heart InstituteArrhythmia Core LaboratoryPrnewswire Milestone Pharmaceuticals IncCenters For DiseaseUs Securities Exchange CommissionMilestone Pharmaceuticals IncArrhythmia ResearchHeart Rhythm SocietyAmerican College Of CardiologyPiedmont Heart InstituteDuke Clinical Research InstituteExchange CommissionMilestone PharmaceuticalsChief Executive OfficerHeart RhythmReport Topline DataMid Second HalfNew Drug Application